A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.

Kreye J, Reincke SM, Kornau HC, Sánchez-Sendin E, Corman VM, Liu H, Yuan M, Wu NC, Zhu X, Lee CD, Trimpert J, Höltje M, Dietert K, Stöffler L, von Wardenburg N, van Hoof S, Homeyer MA, Hoffmann J, Abdelgawad A, Gruber AD, Bertzbach LD, Vladimirova D, Li LY, Barthel PC, Skriner K, Hocke AC, Hippenstiel S, Witzenrath M, Suttorp N, Kurth F, Franke C, Endres M, Schmitz D, Jeworowski LM, Richter A, Schmidt ML, Schwarz T, Müller MA, Drosten C, Wendisch D, Sander LE, Osterrieder N, Wilson IA, Prüss H. · 2020

Read A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. by Kreye J, Reincke SM, Kornau HC, Sánchez-Sendin E, Corman VM, Liu H, Yuan M, Wu NC, Zhu X, Lee CD, Trimpert J, Höltje M, Dietert K, Stöffler L, von Wardenburg N, van Hoof S, Homeyer MA, Hoffmann J, Abdelgawad A, Gruber AD, Bertzbach LD, Vladimirova D, Li LY, Barthel PC, Skriner K, Hocke AC, Hippenstiel S, Witzenrath M, Suttorp N, Kurth F, Franke C, Endres M, Schmitz D, Jeworowski LM, Richter A, Schmidt ML, Schwarz T, Müller MA, Drosten C, Wendisch D, Sander LE, Osterrieder N, Wilson IA, Prüss H. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7510528.txt.

Introduction

Kreye and co-authors isolate a protective antibody against SARS-CoV-2 and test it in hamsters. The virus spreads as a pandemic with lung and multi-organ harm. Mapping neutralizing antibodies guides vaccines and care.

From 598 human monoclonal antibodies taken from 10 patients, the team found 40 strong neutralizers. The best, CV07-209, blocked the live virus at an IC50 of 3.1 ng/mL in the lab tests. Crystal structures showed two antibodies blocking the ACE2 docking site head-on. Some near-germline antibodies also reacted with the body's own antigens. CV07-209 did not, and that matters for safety. Given before or after infection, it shielded hamsters from infection, weight loss, and lung damage. The authors back such clean neutralizers as therapy.

Catalog record

CREATORKreye J, Reincke SM, Kornau HC, Sánchez-Sendin E, Corman VM, Liu H, Yuan M, Wu NC, Zhu X, Lee CD, Trimpert J, Höltje M, Dietert K, Stöffler L, von Wardenburg N, van Hoof S, Homeyer MA, Hoffmann J, Abdelgawad A, Gruber AD, Bertzbach LD, Vladimirova D, Li LY, Barthel PC, Skriner K, Hocke AC, Hippenstiel S, Witzenrath M, Suttorp N, Kurth F, Franke C, Endres M, Schmitz D, Jeworowski LM, Richter A, Schmidt ML, Schwarz T, Müller MA, Drosten C, Wendisch D, Sander LE, Osterrieder N, Wilson IA, Prüss H.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE85 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7510528

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model By Jakob Kreye, S Momsen Reincke, Hans-Christian Kornau, Elisa Sánchez-Sendin, Victor Max Corman, Hejun Liu, Meng Yuan, Nicholas C Wu, Xueyong Zhu, Chang-Chun D Lee, Jakob Trimpert, Markus Höltje Published in: Cell DOI: 10.1016/j.cell.2020.09.049 ABSTRACT Summary The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from 10 COVID-19 patients, we identified 40 strongly neutralizing mAbs. The most potent mAb, CV07-209, neutralized authentic SARS-CoV-2 with an IC50 value of 3.1 ng/mL. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 Å revealed a direct block of ACE2 attachment. Interestingly, some of the near-germline SARS-CoV-2-neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss, and lung pathology. Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy. Keywords: COVID-19, SARS-CoV-2, monoclonal antibody, neutralizing antibody, crystal structures, autoreactivity, self-reactivity, self-antigens, hamster model, post-exposure INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started emerging in humans in late 2019 and rapidly became a pandemic with millions of cases worldwide. SARS-CoV-2 infection causes coronavirus disease 2019 (COVID-19) with severe respiratory symptoms, pathological inflammation, and multi-organ dysfunction, including acute respiratory distress syndrome, cardiovascular events, coagulopathies, and neurological symptoms (Helms et al., 2020; Zhou et al., 2020; Zhu et al., 2020). Some aspects of the diverse clinical manifestations may result from a hyperinflammatory response, as suggested by reduced mortality in hospitalized COVID-19 patients under dexamethasone therapy (Horby et al., 2020). Understanding the immune response to SARS-CoV-2 is of utmost importance. Multiple recombinant SARS-CoV-2 monoclonal antibodies (mAbs) from convalescent patients have been reported (Brouwer et al., 2020; Cao et al., 2020; Ju et al., 2020; Kreer et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Wec et al., 2020). mAbs targeting the receptor-binding domain (RBD) of the viral spike protein S1 can compete with its binding to human angiotensin-converting enzyme 2 (ACE2) and prevent virus entry and subsequent replication (Cao et al., 2020; Ju et al., 2020; Walls et al., 2020). Potent virus-neutralizing mAbs that were isolated from diverse variable immunoglobulin (Ig) genes typically carry low levels of somatic hypermutations (SHMs). Several of these neutralizing mAbs selected for in vitro efficacy showed prophylactic or therapeutic potential in animal models (Cao et al., 2020; Liu et al., 2020; Rogers et al., 2020; Zost et al., 2020). The low number of SHMs suggests limited affinity maturation in germinal centers compatible with an acute infection. Near-germline mAbs usually constitute the first line of defense against pathogens but carry the risk of self-reactivity to autoantigens (Lerner, 2016; Liao et al., 2011; Zhou et al., 2007). Although critical for therapeutic use in humans, the potential tissue reactivity of near-germline SARS-CoV-2 antibodies has so far not been examined. Here we systematically selected 18 strongly neutralizing mAbs of 598 antibodies from 10 COVID-19 patients by characterization of their biophysical properties, authentic SARS-CoV-2 neutralization, and exclusion of off-target binding to murine tissue. Additionally, we solved two crystal structures of neutralizing mAbs in complex with the RBD, showing antibody engagement with the ACE2 binding site from different approach angles. Finally, we selected mAb CV07-209 for in vivo evaluation because of its in vitro efficacy and absence of tissue reactivity. Systemic application of CV07-209 in a hamster model of SARS-CoV-2 infection led to a profound reduction of clinical, paraclinical, and histopathological COVID-19 pathology, reflecting its potential for translational application in patients with COVID-19. RESULTS Antibody Repertoire Analysis of COVID-19 Patients We first characterized the B cell response in COVID-19 using single-cell Ig gene sequencing of human mAbs (Figure 1A). From 10 COVID-19 patients with serum antibodies to the S1 subunit of the SARS-CoV-2 spike protein (Figure S1A; Table S1), we isolated two populations of single cells from peripheral blood mononuclear cells with fluorescence-activated cell sorting (FACS): CD19+CD27+CD38+ antibody-secreting cells (ASCs) reflecting the overall humoral immune response and SARS-CoV-2-S1-labeled CD19+CD27+ memory B cells (S1-MBCs) for characterization of antigen-specific responses (Figures S1B and S1C). We obtained 598 functional paired heavy- and light-chain Ig sequences (Table S2). Of 432 recombinantly expressed mAbs, 122 were reactive to SARS-CoV-2-S1 (S1+) with a frequency of 0.0%–18.2% (median, 7.1%) within ASCs and 16.7%–84.1% (median, 67.1%) within S1-MBCs (Figures 1B and 1C). Binding to S1 did not depend on affinity maturation, as measured by the number of SHMs (Figure 1D). Compared with mAbs not reactive to SARS-CoV-2-S1, S1+ mAbs had fewer SHMs but equal lengths of their light- and heavy-chain complementarity-determining region 3 (CDR3) (Figures S1D–S1F). Within the ASC and S1-MBC population, 45.0% and 90.2% of S1+ mAbs, respectively, bound the RBD (Figure S1G). [Figure: Identification and Characterization of Potent SARS-CoV-2-Neutralizing mAbs(A) Diagram depicting the strategy for isolation of 18 potently neutralizing mAbs (top 18).(B) Normalized binding to S1 of SARS-CoV-2 for mAbs isolated from ASCs (inverted triangles; blue, S1-binding; gray, not S1-binding). OD, optical density in ELISA.(C) Normalized binding to S1 of SARS-CoV-2 for mAbs isolated from S1-stained MBCs (triangles; colors as in B).(D) S1-binding plotted against the number of somatic hypermutations (SHMs) for all S1-reactive mAbs.(E) Concentration-dependent binding of the top 18 SARS-CoV-2 mAbs to the RBD of S1 (mean ± SD from two wells of one experiment).(F) Concentration-dependent neutralization of authentic SARS-CoV-2 plaque formation by the top 18 mAbs (mean ± SD from two independent measurements).(G) Apparent affinities of mAbs to RBDs (KD determined by surface plasmon resonance) plotted against IC50 of authentic SARS-CoV-2 neutralization.See also Figures S1, S2, S3, S4, and S5 and Tables S1, S2, and S3.] [Figure: SARS-CoV-2-S1 Serum IgG Response from COVID-19 Patients, Flow Cytometry Gating, and Characteristics of Ig Sequences, Related to Figure 1 and Tables S1 and S2(A) Serum IgG response determined as the normalized optical density (OD) in a SARS-CoV-2-S1 ELISA in relation to the time point of diagnosis defined by the first positive qPCR test. Upward arrowhead denotes the appearance of first symptoms. Downward arrowhead denotes the PBMC isolation. From patient CV01, PBMC samples were isolated at two time points as indicated by the second downward arrow with an asterisk (∗).(B-C) A representative flow cytometry plot from patient CV38 indicating gating on (B) CD19+CD27+antibody-secreting cells (ASC) and (C) SARS-CoV-2-S1-stained memory B cells (S1-MBC). Cells were pre-gated on live CD19+ B cells.(D) Comparison of somatic hypermutation (SHM) count within immunoglobulint V genes combined from heavy and light chains of S1-reactive (S1+, blue) and non-S1-reactive (S1-, gray) mAbs. Statistical significance was determined using a Kruskal-Wallis test with Dunn’s multiple comparison test. (ASC: n = 20 S1+, n = 260 S1-; S1-MBC: n = 102 S1+, n = 50 S1-, n-values represent number of mAbs). All expressed mAbs are displayed. Each triangle represents one mAb, isolated from an ASC (inverted triangle) or a S1-MBC (triangle). Bars indicate mean.(E-F) Length comparison of complementarity-determining region (CDR) 3 amino acid sequences between S1+ and S1- mAbs within (E) heavy and (F) light chains. Bars indicate mean. Symbols and colors have the same meaning as in (D).(G) Frequency of

Read the complete text